Pharmaceutical compositions

A pharmaceutical composition for oral administration comprising (1S,4R)-cis-4-[(2-amino-6-cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol, or a pharmaceutically acceptable derivative thereof, together with citrate and at least one sweetener selected from sorbitol and saccharin, at a pH range of 6.6 to 7.5.

A process for formulating (1S,4R)-cis-4-[(2-amino-6-cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol for oral administration comprising the step of bringing (1S,4R)-cis-4-[(2-amino-6-cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol, or a pharmaceutically acceptable derivative thereof, into association with citrate and a sweetening agent which does not contain a carboxyl group.

A pharmaceutical composition for oral administration comprising (1S,4R)-cis-4-[2-amino-6-cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol, or a pharmaceutically acceptable derivative thereof, citrate, and a sweetening agent compatible with said (1S,4R)-cis-4-[2-amino-6-cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol, or pharmaceutically acceptable derivative thereof.